Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Receivables: 2012-2025

Historic Receivables for Veracyte (VCYT) over the last 12 years, with Sep 2025 value amounting to $47.8 million.

  • Veracyte's Receivables fell 2.01% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $198.9 million, marking a year-over-year increase of 6.87%. This contributed to the annual value of $46.5 million for FY2024, which is 15.22% up from last year.
  • As of Q3 2025, Veracyte's Receivables stood at $47.8 million, which was down 5.88% from $50.8 million recorded in Q2 2025.
  • Veracyte's 5-year Receivables high stood at $53.8 million for Q1 2025, and its period low was $27.9 million during Q1 2021.
  • For the 3-year period, Veracyte's Receivables averaged around $46.6 million, with its median value being $46.7 million (2024).
  • In the last 5 years, Veracyte's Receivables spiked by 128.65% in 2021 and then dropped by 8.28% in 2023.
  • Veracyte's Receivables (Quarterly) stood at $41.5 million in 2021, then increased by 6.17% to $44.0 million in 2022, then fell by 8.28% to $40.4 million in 2023, then rose by 15.22% to $46.5 million in 2024, then fell by 2.01% to $47.8 million in 2025.
  • Its last three reported values are $47.8 million in Q3 2025, $50.8 million for Q2 2025, and $53.8 million during Q1 2025.